| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT07518186 A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or… |
Recruitment opened |
| 2026-06-06 | NCT07518186 A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or… |
Trial sites expanded: 0 -> 8 locations |
| 2026-06-06 | NCT07266441 A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma |
Trial sites expanded: 37 -> 51 locations |
| 2026-06-06 | NCT07258511 A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3… |
Trial sites expanded: 43 -> 65 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-15 | NCT07589634 A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07258511 | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3… | Multiple Myeloma | Recruiting |
| NCT07518186 | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or… | Multiple Myeloma | Recruiting |
| Phase 2 | |||
| NCT06500884 | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | Multiple Myeloma | Recruiting |
| NCT07266441 | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | Recruiting |
| NCT07589634 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release… | Multiple Myeloma | Not Yet Recruiting |
| Phase 1 | |||
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or… | Multiple Myeloma | Recruiting |
| NCT05652335 | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or… | Relapsed or Refractory Multiple Myeloma | Recruiting |